Literature DB >> 25363824

XAS studies of Se speciation in selenite-fed rats.

Claire M Weekley1, Jade B Aitken, Paul K Witting, Hugh H Harris.   

Abstract

The biological activity of selenium is dependent on its chemical form. Therefore, knowledge of Se chemistry in vivo is required for efficacious use of selenium compounds in disease prevention and treatment. Using X-ray absorption spectroscopy, Se speciation in the kidney, liver, heart, spleen, testis and red blood cells of rats fed control (∼0.3 ppm Se) or selenite-supplemented (1 ppm or 5 ppm Se) diets for 3 or 6 weeks, was investigated. X-ray absorption spectroscopy revealed the presence of Se-Se and Se-C species in the kidney and liver, and Se-S species in the kidney, but not the liver. X-ray absorption near edge structure (XANES) spectra showed that there was variation in speciation in the liver and kidneys, but Se speciation was much more uniform in the remaining organs. Using principal component analysis (PCA) to interpret the Se K-edge X-ray absorption spectra, we were able to directly compare the speciation of Se in two different models of selenite metabolism--human lung cancer cells and rat tissues. The effects of Se dose, tissue type and duration of diet on selenium speciation in rat tissues were investigated, and a relationship between the duration of the diet (3 weeks versus 6 weeks) and selenium speciation was observed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25363824      PMCID: PMC4244600          DOI: 10.1039/c4mt00227j

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  49 in total

Review 1.  Lessons from basic research in selenium and cancer prevention.

Authors:  C Ip
Journal:  J Nutr       Date:  1998-11       Impact factor: 4.798

Review 2.  An edge with XAS.

Authors:  G N George; B Hedman; K O Hodgson
Journal:  Nat Struct Biol       Date:  1998-08

3.  Selenium and coronary heart disease: a meta-analysis.

Authors:  Gemma Flores-Mateo; Ana Navas-Acien; Roberto Pastor-Barriuso; Eliseo Guallar
Journal:  Am J Clin Nutr       Date:  2006-10       Impact factor: 7.045

4.  Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase.

Authors:  M Björnstedt; S Kumar; A Holmgren
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

5.  Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.

Authors:  T Yamaguchi; K Sano; K Takakura; I Saito; Y Shinohara; T Asano; H Yasuhara
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

6.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

Authors:  L C Clark; G F Combs; B W Turnbull; E H Slate; D K Chalker; J Chow; L S Davis; R A Glover; G F Graham; E G Gross; A Krongrad; J L Lesher; H K Park; B B Sanders; C L Smith; J R Taylor
Journal:  JAMA       Date:  1996-12-25       Impact factor: 56.272

7.  Selenoprotein P is required for mouse sperm development.

Authors:  Gary E Olson; Virginia P Winfrey; Subir K Nagdas; Kristina E Hill; Raymond F Burk
Journal:  Biol Reprod       Date:  2005-03-02       Impact factor: 4.285

8.  Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study.

Authors:  O Olivieri; A M Stanzial; D Girelli; M T Trevisan; P Guarini; M Terzi; S Caffi; F Fontana; M Casaril; S Ferrari
Journal:  Am J Clin Nutr       Date:  1994-10       Impact factor: 7.045

9.  Selenium prevents tumor development in a rat model for chemical carcinogenesis.

Authors:  Linda Björkhem-Bergman; Ulla-Britta Torndal; Servet Eken; Christina Nyström; Arrigo Capitanio; Erik Huusfeldt Larsen; Mikael Björnstedt; Lennart C Eriksson
Journal:  Carcinogenesis       Date:  2004-09-30       Impact factor: 4.944

10.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

Authors:  L C Clark; B Dalkin; A Krongrad; G F Combs; B W Turnbull; E H Slate; R Witherington; J H Herlong; E Janosko; D Carpenter; C Borosso; S Falk; J Rounder
Journal:  Br J Urol       Date:  1998-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.